<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947529</url>
  </required_header>
  <id_info>
    <org_study_id>MD2016</org_study_id>
    <nct_id>NCT02947529</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Use in Acute Hip Fractures</brief_title>
  <official_title>The Use of Tranexamic Acid to Reduce the Need for Transfusion 1 Week Post-operatively for Hemiarthroplasty or Intramedullary Nailing Needed to Correct Acute Hip Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carilion Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carilion Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Tranexamic acid (TXA) has been used widely for the reduction of post operative
      blood loss for various orthopaedic procedures including but not limited to total hip
      arthroplasty and total knee arthroplasty. A recent multihospital meta-analysis conducted in
      2013 showed that patients who received TXA showed a significant reduction in post-operative
      transfusion (20.1% to 7.7%). The procedures we will be evaluating are the intramedullary
      nail for intertrochanteric fracture and hip hemiarthroplasty. These procedures are similar
      to the total hip or knee replacement in that they can result in significant blood loss that
      requires a post operative transfusion.

      STUDY PURPOSE: To determine the efficacy of TXA to decrease the rate of post-operative
      transfusion for acute hip fractures repaired with the following two methods, intramedullary
      nailing for intertrochanteric fracture and hemiarthroplasty.

      METHODS: The model for the study is a prospective randomized control trial. Patients will be
      placed in one of two arms of the study after passing our inclusion criteria. The arms will
      be for either the intramedullary nailing for intertrochanteric fracture or for
      hemiarthroplasty. These two categories will be subdivided into those receiving TXA and those
      not receiving TXA. The patients in each category will have standard post-operative care and
      laboratory testing. We will record the patients in either arm of the study, whether it be no
      TXA or TXA, who require post-operative transfusion within 1 week of the operation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion reduction rate</measure>
    <time_frame>1 week</time_frame>
    <description>Determine the efficacy of Tranexamic Acid (TXA) in the reduction of allogenic blood transfusion within 1 week following either hemiarthroplasty or intramedullary nailing for intertrochanteric fracture.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tranexamic acid post operative complications</measure>
    <time_frame>1 year</time_frame>
    <description>Determine what effect TXA has on post-operative complications within 1 year following surgery for either hemiarthroplasty or intramedullary nailing for intertrochanteric fracture.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Hemiarthroplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramedullary nail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Hemiarthroplasty</arm_group_label>
    <arm_group_label>Intramedullary nail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Hemiarthroplasty</arm_group_label>
    <arm_group_label>Intramedullary nail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Geriatric patients age 65 or older who require surgery for a low energy trauma hip
             fracture

        Exclusion Criteria:

          -  Prothrombotic state

          -  Cardiac stent within the past year with corresponding antiplatelet therapy

          -  Mechanical heart valves

          -  Deep vein thrombosis history

          -  Aortic stenosis

          -  Currently on Coumadin

          -  Malignancy

          -  Kidney dialysis

          -  Non-English speaking patients

          -  Medications contraindicated with tranexamic acid.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trevor Owen, MD</last_name>
    <phone>540-725-1226</phone>
    <email>tmowen@carilionclinic.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trevor Owen, MD</last_name>
      <phone>540-725-1226</phone>
      <email>tmowen@carilionclinic.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014 Aug 12;349:g4829. doi: 10.1136/bmj.g4829.</citation>
    <PMID>25116268</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>October 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemiarthroplasty</keyword>
  <keyword>Intramedullary nail</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
